Amphastar Pharmaceuticals Inc. (AMPH) Insider Jason B. Shandell Sells 56,996 Shares
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) insider Jason B. Shandell sold 56,996 shares of the stock in a transaction that occurred on Monday, September 26th. The stock was sold at an average price of $19.50, for a total value of $1,111,422.00. Following the transaction, the insider now owns 259,957 shares in the company, valued at approximately $5,069,161.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) opened at 19.57 on Thursday. The company has a 50 day moving average price of $19.16 and a 200 day moving average price of $15.70. The firm has a market cap of $883.02 million, a PE ratio of 63.54 and a beta of 1.83. Amphastar Pharmaceuticals Inc. has a 12-month low of $10.50 and a 12-month high of $21.53.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Monday, August 8th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.22. The firm had revenue of $68 million for the quarter, compared to analyst estimates of $62.10 million. Amphastar Pharmaceuticals had a net margin of 5.19% and a return on equity of 4.71%. Amphastar Pharmaceuticals’s quarterly revenue was up 26.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.09) earnings per share. On average, analysts forecast that Amphastar Pharmaceuticals Inc. will post $0.37 earnings per share for the current fiscal year.
A number of equities analysts have issued reports on AMPH shares. BMO Capital Markets started coverage on Amphastar Pharmaceuticals in a research report on Tuesday, June 28th. They set a “market perform” rating and a $17.00 price target on the stock. Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a report on Monday, August 1st. Piper Jaffray Cos. reissued an “overweight” rating and set a $22.00 target price on shares of Amphastar Pharmaceuticals in a report on Thursday, August 11th. Jefferies Group increased their target price on Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday, August 9th. Finally, Needham & Company LLC increased their target price on Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, August 9th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $20.00.
Large investors have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC raised its stake in Amphastar Pharmaceuticals by 57.5% in the second quarter. Acrospire Investment Management LLC now owns 6,791 shares of the company’s stock valued at $109,000 after buying an additional 2,479 shares during the period. Envestnet Asset Management Inc. acquired a new stake in Amphastar Pharmaceuticals during the first quarter valued at $115,000. C M Bidwell & Associates Ltd. acquired a new stake in Amphastar Pharmaceuticals during the second quarter valued at $207,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Amphastar Pharmaceuticals during the first quarter valued at $180,000. Finally, Bank of Montreal Can acquired a new stake in Amphastar Pharmaceuticals during the second quarter valued at $292,000. Hedge funds and other institutional investors own 35.87% of the company’s stock.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Stock Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.